Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
Sarkozy C, Callanan MB, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre EA, Le Gouill S. Sarkozy C, et al. Among authors: joubert c. Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944. Online ahead of print. Blood. 2024. PMID: 38669626
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA.
Tessoulin B, Bouabdallah K, Burroni B, Lamy T, Gressin R, Cartron G, Thieblemont C, Sarkozy C, Haioun C, Casasnovas O, Joubert C, Gyan E, Hermine O, Le Gouill S. Tessoulin B, et al. Among authors: joubert c. Ann Hematol. 2020 Aug;99(8):1771-1778. doi: 10.1007/s00277-020-04159-3. Epub 2020 Jun 29. Ann Hematol. 2020. PMID: 32601796 Clinical Trial.
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.
Tessoulin B, Chiron D, Thieblemont C, Oberic L, Bouadballah K, Gyan E, Damaj G, Ribrag V, Gressin R, Feugier P, Casasnovas O, Zerazhi H, Lemonnier F, Maisonneuve H, Joubert C, Van Den Neste E, Lamy T, Tilly H, Moreau A, Hermine O, Le Gouill S. Tessoulin B, et al. Among authors: joubert c. Bone Marrow Transplant. 2021 Jul;56(7):1700-1709. doi: 10.1038/s41409-020-01198-2. Epub 2021 Mar 3. Bone Marrow Transplant. 2021. PMID: 33658645 Free article. Clinical Trial.
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot JM, Molina TJ, Bosly A, Joubert C, Haioun C, Nicolas-Virelizier E, Feugier P, Fitoussi O, Delarue R, Tilly H. Camus V, et al. Among authors: joubert c. Blood Adv. 2022 Dec 27;6(24):6169-6179. doi: 10.1182/bloodadvances.2022007609. Blood Adv. 2022. PMID: 35737565 Free PMC article.
Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.
Chevreux S, de Barros S, Laurent C, Durand A, Delpierre C, Robert P, Joubert C, Griolet S, Kanoun S, Bastie JN, Casasnovas RO, Rossi C. Chevreux S, et al. Among authors: joubert c. Cancers (Basel). 2022 Dec 22;15(1):53. doi: 10.3390/cancers15010053. Cancers (Basel). 2022. PMID: 36612050 Free PMC article.
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac AC, Moatti H, Fornecker LM, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau AS, Casasnova RO. Rossi C, et al. Among authors: joubert c. Haematologica. 2022 Dec 1;107(12):2897-2904. doi: 10.3324/haematol.2021.280004. Haematologica. 2022. PMID: 35638548 Free PMC article.
Fine-tuning FAM161A gene augmentation therapy to restore retinal function.
Arsenijevic Y, Chang N, Mercey O, El Fersioui Y, Koskiniemi-Kuendig H, Joubert C, Bemelmans AP, Rivolta C, Banin E, Sharon D, Guichard P, Hamel V, Kostic C. Arsenijevic Y, et al. Among authors: joubert c. EMBO Mol Med. 2024 Apr;16(4):805-822. doi: 10.1038/s44321-024-00053-x. Epub 2024 Mar 19. EMBO Mol Med. 2024. PMID: 38504136 Free PMC article.
Neuro damage control: current concept and civilian applications.
Manet R, Joubert C, Balanca B, Taverna XJ, Monneuse O, David JS, Dagain A. Manet R, et al. Among authors: joubert c. Neurochirurgie. 2023 Nov;69(6):101505. doi: 10.1016/j.neuchi.2023.101505. Epub 2023 Oct 8. Neurochirurgie. 2023. PMID: 37806039 Review.
The fate of mitochondria during platelet activation.
Grichine A, Jacob S, Eckly A, Villaret J, Joubert C, Appaix F, Pezet M, Ribba AS, Denarier E, Mazzega J, Rinckel JY, Lafanechère L, Elena-Herrmann B, Rowley JW, Sadoul K. Grichine A, et al. Among authors: joubert c. Blood Adv. 2023 Oct 24;7(20):6290-6302. doi: 10.1182/bloodadvances.2023010423. Blood Adv. 2023. PMID: 37624769 Free PMC article.
226 results